Krebs Biochemicals & Industries has announced a net loss of Rs 16.93 crore for FY26 as the company continues to grapple with the closure of its Vizag unit. To secure its future, the board has approved a merger with promoter Ipca Laboratories, while seeking shareholder approval for Rs 120 crore in related party transactions to maintain operations.
Krebs Biochemicals Reports FY26 Loss and Announces Strategic Merger with Ipca Labs
Net Loss: Rs 16.93 crore | Negative Net Worth: Rs 162.75 crore
Reader Takeaway: The proposed Ipca Labs merger is a vital lifeline, yet the Vizag plant closure creates significant uncertainty.
What just happened
Krebs Biochemicals & Industries Limited has reported its financial results for the year ended March 31, 2026, posting a net loss of Rs 16.93 crore. In a significant strategic move, the board of directors has approved a Scheme of Amalgamation with its promoter, Ipca Laboratories Limited, effective from April 1, 2026. The company is also seeking shareholder approval for related party transactions with Ipca Laboratories amounting to Rs 120 crore annually to support working capital and technical requirements.
Why this matters
The company’s primary manufacturing facility in Vizag has been non-operational since February 9, 2025, following a stop-production order from the Andhra Pradesh Pollution Control Board. This suspension has severely restricted production capacity and revenue generation, contributing to the persistent financial strain. The merger with Ipca Laboratories is intended to provide the necessary stability and resources to navigate these operational hurdles.
The backstory
Financial stress has been mounting for the firm, with the company’s net worth slipping further into negative territory at Rs 162.75 crore. Independent auditors have raised a red flag regarding the company’s ability to continue as a going concern, citing the recurring losses and liabilities. Management has stated that it holds a commitment from Ipca Laboratories for financial support to meet obligations until the business achieves operational viability.
Risks to watch
- Ongoing closure of the Vizag plant due to environmental non-compliance.
- High reliance on Ipca Laboratories for financial support.
- The merger is subject to multiple regulatory and shareholder approvals, which adds a layer of uncertainty for investors.
What to track next
Investors should closely monitor the timeline for the merger approval process and any updates regarding the potential revocation of the pollution control order currently affecting the Vizag unit.